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Abstract Attention deficit/hyperactivity disorder (ADHD)
involves clinically heterogeneous problems including atten-
tion deficits, behavioural hyperactivity and impulsivity. Sev-
eral animal models of ADHD have been proposed, ranging
from models with neurotoxic lesions to genetically manipu-
lated animals. An ADHD model is supposed to show phe-
nomenological similarities with the disorder, i.e. it should
mimic the three core symptoms (face validity). A model
should also conform to an established or hypothesized path-
ophysiological basis of the disorder (construct validity).
Finally, an animal model should be able to predict previously
unknown aspects of the neurobiology of ADHD or to provide
potential new treatments (predictive validity). The currently
proposed models are heterogeneous with regard to their
pathophysiological alterations and their ability to mimic
behavioural symptoms and to predict response to medication.
This might reflect the heterogeneous nature of ADHD. Since
the knowledge about the biology of ADHD from human
studies is limited, one cannot at present decide which model
best represents ADHD or certain ADHD subtypes. Animal
models with good face and predictive validity may be useful
for investigations of the underlying biological substrates of
ADHD. At present, the models in use should be described as
animal models of ADHD-like symptoms rather than models of
ADHD.
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Introduction
The definition of hyperkinetic disorder according to ICD-10
is based upon the simultaneous presence of three main
behavioural problems, i.e. attention deficit, overactivity
and impulsiveness. They need to be present in more than
one situation and to cause impairment in functioning. The
problems need also to have been present before the age of 7
years. The DSM-IV category is called attention deficit/
hyperactivity disorder (ADHD). The criteria are based
upon the same list of behaviours as those that characterize
the ICD-10 definition of hyperkinetic disorder.
The 4th edition of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) describes three subtypes of
ADHD, i.e. (1) the predominantly inattentive type, (2) the
predominantly hyperactive/impulsive type and (3) the
combined type with symptoms of inattention, impulsivity
and hyperactivity (American Psychiatric Association
1994). ADHD represents the extremes of normal behaviour
in the domains of attention and activity, which makes a
clear diagnosis difficult. In addition, several comorbid
disorders can be found in children and adolescents with
ADHD, including oppositional defiant disorder and con-
duct disorder (50%), anxiety disorders (25–35%), mood
disorders (15%) and learning disabilities (Biederman et al.
1991). In view of the high prevalence of comorbid disor-
ders, clinical, neuropsychological and neuroimaging
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studies of children and adolescents with ADHD will consist
of relatively heterogeneous patient groups. It is therefore
important to describe the core disorder of ADHD, e.g. by
identifying biological markers, which could improve the
diagnosis. This may also help to develop new treatment
strategies.
The current pharmacotherapy with psychostimulants
goes back to 1937 when Bradley discovered that amphet-
amines ameliorate disruptive behaviour in children (Bradley
1937). All drugs that are found to be therapeutically
effective in ADHD affect central catecholaminergic neu-
rotransmission, namely the dopaminergic and noradrener-
gic systems.
These findings suggest that dysfunctions of catechol-
aminergic neurotransmitter systems contribute to the
symptoms of ADHD. In addition, patients with frontal
brain lesions show some behavioural similarities with
ADHD patients (Benton 1991; Heilman et al. 1991; Levin
1938; Mattes 1980) and ADHD has been shown to be
highly heritable (Bobb et al. 2005; Fisher et al. 2002;
Teicher et al. 2000). These findings suggest that ADHD is
based on some specific neurobiological dysfunctions.
Several animal models of ADHD have been suggested
and discussed (for review see also Kostrzewa et al. 2008;
Russell et al. 2005; Sagvolden et al. 2005; van der Kooij
and Glennon 2007). The quality of these animal models
depends on their ability to mimic the symptoms and to
reflect the neurobiology of ADHD. Most models are solely
based on similarities in symptoms. Since our knowledge
concerning the neurobiological alterations in ADHD
remains sketchy, it is too early to propose valid animal
models of ADHD. The present review will come to the
conclusion that none of the currently discussed models
fulfil all necessary validation criteria.
Human studies in ADHD
Genetics
Several investigations have shown that genetic factors play
a major role in the aetiology of ADHD. The risk to develop
ADHD in siblings of an affected child is between 10% and
up to 32% (Biederman et al. 1992, 1995; Levy and Hay
2001; Smidt et al. 2003). If a parent has ADHD, the risk for
offspring to develop the disorder is 57% (Biederman et al.
1995). In twin studies, it was found that the concordance
for ADHD is 81% in monozygotic twins, compared with
29% in dizygotic twins (Gilger et al. 1992). The average
heritability for ADHD was found to be 0.80–0.90 (Gilger
et al. 1992; Rhee et al. 1999). Although high heritability in
ADHD has been reported in twin, family and adoption
studies, with estimates up to 90%, genome-wide linkage
scans and candidate gene studies have so far not been able
to reliably identify ADHD-associated genes (Faraone et al.
2005).
Hebebrand and associates (2006) reported evidence for a
risk haplotype at the dopamine-transporter (DAT/SLC6A3)
locus based on a linkage scan and subsequent finemapping
of chromosome 5p13. Several novel susceptibility loci
have been detected in a linkage analysis of extended
families using 50K single nucleotide polymorphism (SNP)
array-based genotyping assay (Romanos et al. 2008), one
of these loci, the chromosome 16q locus, contributes to the
genome-wide significant finding revealed by a meta-anal-
ysis comprising data of seven ADHD linkage scans (Zhou
et al. 2008). Although significant linkage signals were
identified in some of the studies, there have been limited
replications between the various independent datasets. The
meta-analysis by Zhou et al. (2008) aimed to identify the
genomic region with most consistent linkage evidence
across the studies. Genome-wide significant linkage was
identified on chromosome 16 between 64 and 83 Mb. In
addition, there were nine other genomic regions showing
nominal or suggestive evidence of linkage.
Several candidate genes have been proposed. The focus
was initially on genes coding for the D2 receptor. An asso-
ciation between this gene and alcoholism, Tourette syn-
drome and ADHD was found (Blum et al. 1996; Comings
et al. 1991). However, other studies failed to replicate these
results (Fisher et al. 2002; Gelernter et al. 1991; Kelsoe et al.
1989). Another promising gene codes for the dopamine D4
receptor. Several studies have suggested that an overrepre-
sentation of this gene is associated with ADHD (Faraone
et al. 1999, 2005; Faraone and Doyle 2001; Grady et al.
2003; LaHoste et al. 1996; Li et al. 2006; Swanson et al.
1998). The D4 receptor is predominantly expressed in pre-
frontal regions, which are thought to be involved in the
aetiology of ADHD (Floresco and Tse 2007; Noain et al.
2006). Several mutations on the D4 receptor gene have been
suggested to be associated with ADHD. The most widely
studied polymorphism is the 48-bp VNTR in exon 3. The
most common alleles are the 2-, 4- and 7-repeat alleles. A
recent meta-analysis by Gizer et al. (2009) has found a
significant association between ADHD and the 7-repeat
allele. This result is in line with other studies (Faraone et al.
2005; Li et al. 2006). Another polymorphism that has been
associated with the D4 receptor, and ADHD is located in the
promoter region of this gene. Some studies have found an
association between ADHD and the 240-bp-allele in the
promoter region of the D4 receptor gene (Kustanovich et al.
2004; McCracken et al. 2000) while other studies were not
able to confirm this association (Barr et al. 2001; Todd et al.
2001). Other authors have suggested a role of the D5 receptor
(Daly et al. 1999; Fisher et al. 2002) or the D1 receptor (Cook
et al. 1995; Daly et al. 1999; Gill et al. 1997; Waldman et al.
2 T. A. Sontag et al.
123
1998). The D1 receptor gene might also be associated with
different responses to methylphenidate in patients with
ADHD (Winsberg and Comings 1999). Genes regulating the
dopamine (DA) metabolism might also play a role, e.g. the
gene regulating dopamine-beta-hydroxylase appears to be
associated with hyperactivity (Mueller et al. 2003). Genes
regulating noradrenergic activity, such as the noradrenaline
(NA) transporter gene (NAT), have been found to be asso-
ciated with ADHD (Barr et al. 2002; Wang et al. 1999).
The serotonin transporter gene has been proposed as a
candidate gene for ADHD and may be involved in the
aetiology of impulsivity (Halperin et al. 1997; Spivak et al.
1999; Stein et al. 1993). One of the most studied poly-
morphisms of this gene (the 5HTTLPR) is located in the
promoter region of this gene. There are two variants, the
long variant is associated with a more rapid serotonin
reuptake and the short variant is associated with a reduced
serotonin uptake (Lesch et al. 1996). A meta-analysis by
Gizer et al. (2009) found a significant but modest associ-
ation between ADHD and the long variant, which supports
the importance of this gene in the aetiology of ADHD. In
the same study, Gizer et al. (2009) also investigated the
serotonin 1B receptor and serotonin 2A receptor genes. An
association between ADHD and the serotonin 1B receptor
had been reported by Hawi et al. (Hawi et al. 2002), and
this was confirmed in the meta-analysis by Gizer et al.
(2009). No association was observed between the serotonin
2A receptor and ADHD (Gizer et al. 2009).
In summary, several genes related to DA, NA and
serotonin appear to be involved in the aetiology of ADHD
(Bobb et al. 2005; DiMaio et al. 2003; Gizer et al. 2009),
Both genome-wide linkage scans and the results of gen-
ome-wide association studies are contradictory concerning
the ‘classic’ genes of the dopaminergic (e.g. DAT/SLC6A3;
COMT), noradrenergic and serotonergic pathways (Lesch
et al. 2008; Franke et al. 2009). Other genes not related to
the major neurotransmitters have also been identified, e.g.
the synaptosomal-associated protein 25 gene (Gizer et al.
2009). New findings from genome-wide association studies
provide additional support for common effects of genes
coding for cell adhesion molecules (e.g., CDH13, ASTN2)
and regulators of synaptic plasticity (e.g. CTNNA2) (Lesch
et al. 2008).
Even though many associations between candidate
genes and ADHD have failed despite a plausible aetio-
logical relevance (Gizer et al. 2009), a combination of
several genes is likely to be involved in ADHD.
Functional and structural abnormalities
There is a striking similarity in symptoms between patients
with lesions in the prefrontal cortex (PFC) and individuals
with ADHD (Benton 1991; Heilman et al. 1991; Levin
1938; Mattes 1980), which suggests an important role of
the PFC in ADHD. Three studies using magnetic resonance
imaging (MRI) found a decreased volume of the right PFC
in children with ADHD, while no such result was found
regarding the left PFC (Castellanos et al. 1996b; Filipek
et al. 1997; Hynd et al. 1990). Other brain nuclei including
the basal ganglia were also found to be altered. For
example, two studies described a reduced volume of the
left caudate nucleus in children with ADHD (Filipek et al.
1997; Hynd et al. 1993). Two further studies found a
reduced volume of the globus pallidus in children with
ADHD compared to normal controls (Aylward et al. 1996;
Castellanos et al. 1996b). However, whereas Castellanos
et al. (1996b) observed a volume reduction in the right
pallidum, Aylward et al. (1996) found a smaller left pal-
lidum. Even more important is the observation that the size
of the basal ganglia and the right frontal lobe appears to
correlate with the degree of impairment in attention and
inhibition in children with ADHD (Casey et al. 1997;
Semrud-Clikeman et al. 2000).
The volumes of several regions of the corpus callosum,
such as the anterior genu (Hynd et al. 1991), rostral body
regions (Baumgardner et al. 1996; Giedd et al. 1994) and
splenial regions (Hynd et al. 1991; Semrud-Clikeman et al.
1994) have also been shown to be reduced in ADHD. Other
brain regions including the temporal lobe, insula, hippo-
campus, amygdala or the central grey did not differ
between children with ADHD and controls (Castellanos
et al. 1996b; Filipek et al. 1997).
Some studies have reported a reduced cerebellar vol-
ume, especially concerning the vermis, in children with
ADHD (Castellanos et al. 1996b, 2001, 2002; Durston et al.
2004). The meaning of this finding is not entirely clear.
Some studies have shown a close connection between the
cerebellum and certain parts of the PFC. It has been sug-
gested that there are anatomically separate output channels
of the cerebellum to the PFC and back to the pons, which is
the main input to the cerebellum (Middleton and Strick
1997a, b, 2001). These data suggest a circuit involved in
cognition between the cerebellum and the PFC. Further-
more, based on observations in patients with cerebellar
tumours, a cerebellar cognitive affective syndrome was
postulated (Schmahmann 2004; Schmahmann and Sherman
1998), which is characterized by deficits in executive
functions, disturbed spatial orientation and uninhibited
behaviour. All these disturbances can also be observed in
ADHD. The cerebellum may therefore play a role in
ADHD.
Several single photon emission computed tomography
(SPECT) studies have shown a reduced blood flow in
prefrontal regions and the connecting pathways to the
limbic system and cerebellum (Lou et al. 1984, 1989, 1990;
Sieg et al. 1995). Even more interesting is the fact that the
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reduction in blood flow in these regions is reversed by
methylphenidate (Langleben et al. 2002; Lou et al. 1984,
1989).
In a PET study, Zametkin et al. (1990) found a reduced
glucose metabolism in striatum, thalamus, hippocampus,
cingulate regions and most prominently in the premotor
and superior PFC. Subsequent studies, however, found no
overall alterations in these regions (Ernst et al. 1994;
Zametkin et al. 1993). Post-hoc analyses revealed a
reduced glucose metabolism in females but not in males
with ADHD (Ernst et al. 1994, 1997; Zametkin et al. 1993).
In summary, structural and functional abnormalities
have been observed within the prefronto-striato-cerebellar
network suggesting an important role of this system in
ADHD. Evidence in support of this hypothesis is that
children with ADHD show different activation patterns
during attention and inhibition tasks within prefrontal
regions, basal ganglia and cerebellum (Rubia et al. 1999;
Teicher et al. 2000; Vaidya et al. 1998; Yeo et al. 2003).
Neurotransmitters
Given the important role of catecholamines in ADHD,
alterations in the metabolism of these neurotransmitters are
to be expected. However, the investigation of urinary levels
of the NA metabolite 3-methoxy-4-hydroxyphenylglycol
(MHPG) has indicated no differences (Rapoport et al.
1978; Wender et al. 1971) or increased levels in ADHD
children compared to control subjects (Shekim et al. 1977,
1979, 1983, 1987).
Oades et al. (1998) found slightly elevated levels of
plasma NA and adrenaline in children with ADHD com-
pared to controls. But there are indications that there is no
correlation between plasma/urine levels of MHPG or the
DA metabolite homovanillic acid (HVA) and the behav-
ioural measures of hyperactivity or aggression. Further-
more, the metabolite levels do not predict the response to
stimulant medications (Castellanos et al. 1994, 1996a).
The assessment of peripheral levels of catecholamine
metabolites has revealed conflicting results, and there are
doubts whether these levels actually reflect the brain neu-
rochemistry in ADHD. A better approach is the measure-
ment of these levels in the central nervous system. A few
studies have investigated neurotransmitter metabolites in
the cerebrospinal fluid (CSF). For example, Shetty and
Chase (1976) found no significant differences in the level
of CSF-HVA between hyperactive children and normal
controls, while Shaywitz et al. (1977) found reduced CSF-
HVA levels in children with minimal brain dysfunction.
However, none of these studies used children with ADHD
according to current diagnostic standards. A more recent
study by Kruesi et al. (1990) found no differences in the
CSF levels of HVA or MHPG in children with disruptive
behaviour, many of whom had ADHD, compared to chil-
dren with obsessive compulsive behaviour. Although these
children were diagnosed with ADHD, they also presented
with disruptive behaviour and, in addition, they were
compared to children with obsessive compulsive behav-
iour. It is therefore difficult to describe the neurotransmitter
status of ADHD children on the basis of this study.
Other studies have attempted to establish a relationship
between stimulant medication and central catecholamine
activity. For example, Reimherr et al. (1984) found in
adults that methylphenidate responders had lower CSF-
HVA levels than non-responders. A predictive value of
CSF-HVA levels for the responsiveness to methylpheni-
date was confirmed by Castellanos et al. (1996a) who,
however, found that increased levels of HVA predicted a
good response to stimulant treatment while low levels were
associated with a worsening of some symptoms. This dis-
crepancy might be explained by the fact that Castellanos
reported on children and Reimherr on adults.
In summary, the findings regarding the neurochemistry
of ADHD are inconsistent. Since heterogeneous patient
groups were used, it is difficult to perform reliable com-
parisons between patients and controls. Furthermore, it is
questionable whether the levels of peripheral neurotrans-
mitter metabolites reflect the neurochemical status of
patients with ADHD, since neither plasma nor urinary
levels of HVA and MHPG correlate with hyperactivity or
predict the response to stimulant treatment (Castellanos
et al. 1994, 1996a). Neurotransmitter metabolite levels in
the CSF provide limited information since they reflect the
overall activity of a neurotransmitter. Concurrently occur-
ring regional increases and reductions in transmitter
activity might offset each other. The above-mentioned
findings clearly underline the contribution of a catechol-
aminergic dysfunction to ADHD.
In ADHD, there appears to be a functional disturbance
within the fronto-striato-cerebellar system affecting the
neurotransmitters DA and NA. These disturbances may be
associated with genes regulating dopaminergic, noradren-
ergic and probably serotonergic functions. The exact nature
of the neurotransmitter dysfunctions is not clear. Further
research is therefore needed in order to elucidate the
neurobiological basis of ADHD. In this context, the
investigation of animal models may be a useful approach.
Dysfunctional systems in ADHD
Mefford and Potter (1989) postulated a noradrenergic
dysfunction of the locus coeruleus (LC) as one of the
earliest models of ADHD. This model was supported by
findings in monkeys, which showed that the LC is involved
in selective processing of sensory stimuli (Aston-Jones
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et al. 1997), which is partly modulated by alpha2-autore-
ceptors (Simson and Weiss 1987). An increase in nor-
adrenaline (NA) suppresses basal firing and enhances
responses to stimuli, i.e. an increase in NA leads to more
focused behaviour, while a reduction in NA would increase
the response to irrelevant stimuli. In addition, adrenaline is
known to inhibit the tonic activity of the LC. A deficit in
one of the two systems might therefore disrupt stimulus-
evoked responding, and this could induce deficits in sus-
tained attention.
In contrast to Mefford and Potter (1989), Pliszka et al.
(1996) suggested a dysfunction in two neurotransmitter
systems. Studies in humans have shown that attention is
distributed in a posterior and anterior system (Posner and
Petersen 1990). The posterior system includes the superior
parietal cortex, the superior colliculus and the pulvinar
nucleus. This system receives a dense innervation from the
LC (Holets 1990). NA enhances the signal-to-noise ratio
and primes, according to Pliszka et al. (1996), the posterior
system to orientate to novel stimuli. Attention then shifts to
the anterior system, which is known to control executive
functions. It consists of the PFC and the anterior cingulate
gyrus. The sensitivity of this system is modulated by DA
from the ventral tegmental area (VTA). According to
Pliszka et al. (1996), a noradrenergic dysfunction could
inhibit the priming of the posterior system and lead to
attention deficits. A loss of DA could induce deficits in the
anterior system and impair executive functions.
A third model suggested by Arnsten et al. (1996) is
based on a dysfunction of the alpha2-autoreceptors in the
prefrontal cortex (PFC). The PFC inhibits the processing of
irrelevant sensory stimuli through connections with the
association cortex (Cavada and Goldman-Rakic 1989) and
therefore protects on-going tasks from interference
(Alexander et al. 1976; Knight et al. 1989). This function is
regulated by the LC, since ascending noradrenergic fibres
stimulate postsynaptic alpha2-adrenoreceptors on the
pyramidal cells in the PFC (Aoki et al. 1994) leading to a
reduction in spontaneous firing (Hasselmo et al. 1997).
Therefore, the activity of the LC primes the PFC to sup-
press task-irrelevant stimuli and inhibits behaviour.
According to Arnsten et al. (1996), a reduced NA activity
causes a partial denervation of the alpha2 receptors in the
PFC, thereby disrupting the inhibitory control of children
with ADHD. Based on this model, the central deficit in
ADHD is a lack of inhibition induced by a decrease in
brain NA.
These models differ but they also have certain points in
common, e.g. the central role of the PFC and catechol-
amine neurotransmitters. The models by Mefford and
Potter (1989), Pliszka et al. (1996) and Arnsten et al.
(1996) emphasize the role of NA in focusing on relevant
stimuli or tasks. Pliszka et al. (1996) and Arnsten et al.
(1996) suggest that a reduced noradrenergic activity con-
tributes to attention deficits and distractibility. However,
these models need to be tested against findings in patients
with ADHD.
Animal models in research
Animal models of diseases are supposed to show phe-
nomenological similarities with the modelled disease. In
animal models of ADHD, one would expect the three core
symptoms of this disorder to be present, i.e. attention
deficits, hyperactivity and impulsivity (Rhee et al. 1999).
These symptom similarities represent the face validity of
the model (Willner 1991). However, as Willner (1991) has
pointed out, face validity also includes a resemblance
regarding aetiology, treatment and the physiological basis
of the modelled disease. Most of these aspects cannot be
used for validation since they are currently objects of
research. Face validity is therefore frequently reduced to
symptom similarities. Validity based on symptom simi-
larities alone might be misleading, since not every hyper-
active rat is a valid model of ADHD. There may be several
alternative reasons why a certain behaviour is observed.
The presence of a certain disease symptom does not nec-
essarily reflect the presence of the entire disease. Further-
more, similar behavioural expression does not necessarily
indicate that this expression has the same biological sub-
strate. This indicates that models based on symptom sim-
ilarities alone are weak and that other criteria are needed
for the validation of an animal model. Willner (1991) has
suggested to check for aspects of construct validity and
predictive validity.
Construct validity means that the model conforms to an
established or hypothesized pathophysiological basis of the
disorder. A disturbance within the fronto-striato-cerebellar
system has been postulated in ADHD. An animal showing
hyperactivity because of alterations in this system has both
construct and face validity. Construct validity is more
important than face validity because it is a certain theo-
retical framework that connects the behavioural symptoms
with the modelled disease.
Another criterion used in validating an animal model is
predictive validity, which is the ability to predict previ-
ously unknown aspects of the genetics, neurobiology and
pathophysiology of a disorder or to provide potential new
treatments. In practice, drugs with similar effects in human
disease and animal model are often used to validate the
model.
In summary, the validity of an animal model should not
solely be based on behavioural similarities. Both construct
and predictive validity have also to be considered. Con-
struct validity depends on the knowledge about the human
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neurobiology of the modelled disease. Since this knowl-
edge is often limited, construct validity is relatively weak.
Animal models of ADHD
Genetic models (Table 1)
The spontaneously hypertensive rat
The spontaneously hypertensive rat (SHR) was initially
developed as a model of hypertension (Okamoto and Aoki
1963) by inbreeding rats of the Wistar-Kyoto strain
(WKY). This rat strain also showed high spontaneous
motor activity suggesting it as an animal model of ADHD
(Moser et al. 1988). Sagvolden and colleagues established
it as one of the best studied animal models of ADHD
(Sagvolden et al. 1992, 1998; Sagvolden 2000). The SHR
shows several major ADHD symptoms such as impulsivity,
learning deficits or a reduced waiting capacity. These
findings suggest a good face validity of this model (Moser
et al. 1988; Sagvolden 2000; Wyss et al. 1992). The deficits
observed are likely to be related to dysfunctioning within
the fronto-striatal system. For example, the SHR has an
impaired release of DA in the prefrontal cortex, nucleus
accumbens and caudate-putamen (Deutch and Roth 1990;
Jones et al. 1995; Myers et al. 1981; Russell et al. 1995,
1998, 2000b; Russell 2000). Young male SHRs have an
increased density of D1 and D5 receptors in the neostriatum
and nucleus accumbens (Carey et al. 1998), and a recent
study by Li et al. (2007) showed that SHRs show a reduced
expression of the D4 receptor gene in the PFC.
In addition, alterations in the noradrenergic system such
as elevated concentrations of NA in the LC, substantia
nigra and PFC have been found (de Villiers et al. 1995).
This finding is in line with an increased NA transmission
and a down-regulation of beta-adrenoreceptors (Myers
et al. 1981). Glutamatergic-induced NA release in the
prefrontal cortex is higher in SHRs than in control WKY
rats (Russell and Wiggins 2000), while the stimulus-
induced release from prefrontal cortex slices does not differ
between these rat strains (Russell et al. 2000a, b). How-
ever, the inhibition of NA release by the alpha2-autore-
ceptor may be deficient (Reja et al. 2002; Russell et al.
2000a, b; Tsuda et al. 1990) suggesting an overall
increased noradrenergic transmission in SHR. Finally, the
behavioural deficits can be attenuated with monoaminergic
agents (Boix et al. 1998; Myers et al. 1982). The SHR
shows therefore several aspects of face validity, construct
validity and predictive validity.
However, hypertension is a confounding factor in this
animal model since it is not associated with ADHD, and it
Table 1 Genetic animal models of ADHD
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cannot be excluded that increased blood pressure affects
behaviour. The behavioural deficits in SHRs might reflect
dysfunctioning or brain damage caused by high blood
pressure. Some human studies have shown a negative
effect of hypertension on cognition (Anstey and Christensen
2000; Birkenhager et al. 2001). Young SHRs do not show
hypertension and Diana (2002) reported no cognitive
decline in aged SHRs compared to WKY rats. These
findings suggest that the cognitive deficits in SHRs do not
depend on hypertension. Both SHRs and WKY rats have
shown a poor performance at the age of 6 months com-
pared to normal Sprague–Dawley rats. This suggests that
both young SHRs and young WKY rats show cognitive
impairment, which does not worsen with increasing age.
This is in support of the SHR as a model of ADHD.
However, the finding that WKY rats have cognitive deficits
puts in question the use of these rats as controls for SHRs.
Interestingly, Pare (1989) reported a decrease in open field
activity in WKY rats compared to Wistar rats and SHRs.
These findings were confirmed by other researchers
(McCarty and Kirby 1982; Sagvolden et al. 1993; Schaefer
et al. 1978). WKY rats have also shown decreased activity
levels in the forced swim test suggesting them as a model
of depression (Lahmame et al. 1997). It is therefore not
surprising that SHRs show increased motor activity when
compared to hypoactive rats. In a recent report, Alsop
(2007) could not show any difference between SHRs and
WKY rats when correcting for different activity levels in
these two strains. As Alsop (2007) pointed out, this does
not necessarily mean that the SHR is of no use as an animal
model of ADHD. However, all studies comparing SHRs
with WKY rats have to be interpreted with care.
In summary, the SHR is a well-studied model, and many
studies have confirmed the necessary validation criteria.
The influence of hypertension and the problematic role of
WKY rats as control animals remain unsolved problems.
The dopamine-transporter knockout mouse
The DA transporter knockout (DAT-KO) mouse lacks the
DA transporter (DAT) gene and shows some ADHD
symptoms such as spontaneous behavioural hyperactivity
(Gainetdinov et al. 1999; Gainetdinov and Caron 2001;
Giros et al. 1996) or deficits in spatial memory (Gainetdinov
et al. 1999; Gainetdinov and Caron 2001). The hyper-
activity observed in DAT-KO mice is associated with a
marked decrease in DA clearance (Jones et al. 1998a),
which is most likely due to the lack of the DAT. This lack
has been shown to induce several compensatory changes
such as a decrease in DA release from nerve terminals
(Gainetdinov et al. 1998; Jones et al. 1998a) so that the
extracellular DA concentration is only increased about
fivefold.
The concentration of DA metabolites has been shown to
vary. HVA is increased, while 3,4-dihydroxyphenylacetic
acid (DOPAC) is unaltered (Jones et al. 1998a). There are
also changes on the postsynaptic side such as a decrease in
D1 and D2 receptor protein and mRNA in the basal ganglia
(Gainetdinov et al. 1998; Jaber et al. 1996, 1999). Para-
doxically, hyperactivity can be inhibited by compounds
such as amphetamine, methylphenidate and cocaine, which
act primarily on the DA transporter (Gainetdinov et al.
1998; Gainetdinov and Caron 2001; Jones et al. 1998b).
This suggests that the therapeutic effects of these com-
pounds in ADHD are not necessarily based on changes in
dopaminergic transmission alone. In line with this is the
finding that the DA concentration in the striatum of
DAT-KO mice is not increased after challenges with the
psychostimulant drugs in a new environment (Gainetdinov
et al. 1998, 1999; Gainetdinov and Caron 2001). Since
these agents also act on the noradrenergic system, it is
likely that the reduction in hyperactivity in the DAT-KO
mouse is based on alterations of the noradrenergic system
rather than the dopaminergic system.
In summary, this mouse model shows some face, con-
struct and predictive validity because of behavioural sim-
ilarities, alterations of the catecholaminergic system and
the effectiveness of psychostimulants. However, animal
models have to be compared with patients, and there are so
far no indications that the DAT is reduced in patients with
ADHD. On the contrary, several studies have found
increased DAT levels in the striatum of adults and children
with ADHD (Cheon et al. 2003; Dougherty et al. 1999;
Krause et al. 2000).
The coloboma mutant mouse
The coloboma mutant mouse was developed using neutron
irradiation (Searle 1966). This mouse shows delayed neu-
rodevelopment and behavioural deficits such as motor
hyperactivity, impulsivity and impaired inhibition in a
delayed reinforcement task (Bruno et al. 2007; Hess et al.
1994, 1996; Heyser et al. 1995; Wilson 2000). The hyper-
activity observed could be reduced by D-amphetamine but
not by methylphenidate (Hess et al. 1996; Wilson 2000).
Since this mouse has a mutation on the SNAP-25 gene, it is
likely that the behavioural deficits are related to a SNAP-25
dysfunction (Hess et al. 1992, 1996; Steffensen et al. 1996).
The SNAP-25 protein is essential for the fusion of the
neurotransmitter vesicle with the presynaptic membrane in
order to release neurotransmitters. This might explain why
the DA release in the dorsal striatum of the coloboma
mutant mouse is almost completely lost (Raber et al. 1997).
In addition, the D2 receptor expression is increased in the
ventral tegmental area and substantia nigra (Jones et al.
2001b).
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Alterations in the noradrenergic system such as an
increased NA concentration in the striatum, LC and nucleus
accumbens were also observed (Jones et al. 2001a). NA
depletion following the administration of the neurotoxin
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) has
been shown to reduce the hyperactivity but not the
impulsivity (Bruno et al. 2007; Jones and Hess 2003). In
line with this is the finding that adrenergic receptor
antagonists also reduce hyperactivity (Bruno and Hess
2006). Taken together, these results suggest that the motor
activity in coloboma mutant mice is related to a hyperac-
tive noradrenergic system.
In summary, the biochemical data suggest that—similar
to the SHR—the coloboma mouse has a hyperactive nor-
adrenergic system and a hypoactive dopaminergic system.
The alterations of the catecholaminergic systems support
the construct validity of this mouse. Face validity is given
by the behavioural deficits, and predictive validity is given
through the effects of amphetamine. However, the role of
the SNAP-25 gene in ADHD remains to be investigated.
Hess and colleagues found no link between ADHD and the
SNAP-25 gene (Hess et al. 1995) whereas findings from
another group suggest a role of SNAP-25 in ADHD (Barr
et al. 2000).
The Naples high-excitability rat
Naples high-excitability (NHE) rats were selected based
on an increased exploration behaviour as assessed in the
lat-maze. This increased activity is dependent on the
environment, e.g. no hyperactivity could be observed in
the rats’ home cage (Sadile 1993) and motor activity
increased with increasing complexity of the environment
(Sadile et al. 1993; Viggiano et al. 2002b, 2003b). In
addition, NHE rats showed deficits in visual-spatial
attention but no deficits in working memory (Aspide
et al. 1998; Gallo et al. 2002; Papa et al. 2000). Further
investigations have shown that these rats have alterations
in the dopaminergic system. For example, tyrosine
hydroxylase, DAT and D2 receptor mRNA are hyperex-
pressed in the PFC, while the D1 receptor is down-reg-
ulated. No such changes have been reported for the
striatum (Viggiano et al. 2002a, b, 2003a, b; Viggiano
and Sadile 2000).
Face validity of this model is supported by the pres-
ence of motor hyperactivity and attentional deficits.
Construct validity is given because these deficits are
probably based on altered dopaminergic function in the
forebrain. However, studies regarding impulsivity or the
effects of psychostimulants on the deficits observed are
still lacking. Therefore, this model has so far no pre-
dictive validity.
The acallosal mouse strain
Acallosal mice show a complete agenesis of the corpus
callosum. This mouse strain presents with learning deficits
(Lipp et al. 1990; Lipp and Wahlsten 1992; Magara et al.
2000) and signs of hyperactivity, such as a reduced number
of brief stops and a decrease in habituation in an open field
(Magara et al. 2000). This behaviour appears to be related
to a functional dominance of the right hemisphere (Magara
et al. 2000). This is interesting since dysfunctioning of the
right hemisphere has also been discussed in human ADHD
(Garcia-Sanchez et al. 1997; Stefanatos and Wasserstein
2001), and reduced sizes of callosal regions have been
found in some patients with ADHD (Baumgardner et al.
1996; Giedd et al. 1994; Hynd et al. 1991; Semrud-
Clikeman et al. 1994). However, whether or not alterations
in the human corpus callosum contribute to the aetiology of
ADHD remains an open question. In addition, information
regarding impulsive behaviour and attentional deficits,
possible alterations in the catecholaminergic system and
the effects of psychostimulants are still lacking. Taken
together, the validity of this model appears to be rather
weak.
The thyroid hormone receptor (TR)-beta(1) transgenic
mouse
A relatively new animal model of ADHD is the TR-beta(1)
transgenic mouse. This mouse carries a mutant human
TRb1 gene, which was derived from a patient diagnosed to
suffer from a resistance to thyroid hormone (RTH) syn-
drome. This rare syndrome is heritable and characterized
by elevated thyroid hormone levels, normal or elevated
levels of thyroid stimulating hormone (TSH), a short stat-
ure, hearing loss and tachycardia (Weiss and Refetoff
2000). Even more interesting is the fact that approximately
70% of children with RTH syndrome meet the diagnostic
criteria for ADHD (Burd et al. 2003). This suggests a
common mechanism related to the thyroid system in both
diseases.
Both patients with the human RTH syndrome and the
transgenic mouse show an increased level of thyroid hor-
mone and normal levels of TSH. In comparison with the
wild type, the TR-beta(1) transgenic mouse is hyperactive
but not impulsive and shows normal attentional functioning
(McDonald et al. 1998). However, using another promoter
for the TRb1 gene, Siesser et al. (2006) were able to induce
impulsivity, inattention and hyperactivity in these mice. As
shown in patients with ADHD and in most animal models,
the locomotor hyperactivity was primarily present in a
familiar environment. Furthermore, an elevated DA turn-
over and the sensitivity to treatment with methylphenidate
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suggest that these behavioural deficits are related to the
catecholaminergic system (Siesser et al. 2006).
Thyroid abnormalities are rare in children with ADHD
(Weiss et al. 1993). The behavioural deficits in this mouse
model were present at adulthood, although elevated levels
of TSH were only found around the age of 33 days. These
findings suggest that a short period of thyroid abnormalities
during brain development might be responsible for the
behavioural phenotype of these mice (Siesser et al. 2006).
A similar mechanism could be possible in humans, which
might explain why thyroid levels are not abnormal in
children with ADHD.
In summary, this model shows good face validity
because all three core symptoms of ADHD are present. It
has predictive validity since these mice are sensitive to the
treatment with methylphenidate. Finally, it shows some
construct validity because of alterations in the catechol-
aminergic system and developmental disturbances.
However, the role of the thyroid system in ADHD is not
entirely clear. One study has suggested that subclinical
maternal thyroid abnormalities may contribute to the
development of ADHD (Haddow et al. 1999). Abnormal
thyroid hormone levels are known to have severe effects on
brain development and cognition (Thompson and Potter
2000). One might therefore assume that alterations in
thyroid system induce deficits in brain development
resulting in the ADHD behavioural phenotype.
Alpha-synuclein lacking mice
The synucleins are a family of three proteins (alpha, beta,
gamma), which are mainly seen in presynaptic terminals
(Nakajo et al. 1993; Totterdell et al. 2004; Totterdell and
Meredith 2005). The alpha-synuclein protein has been
shown to be involved in the pathogenesis of Parkinson’s
disease (Chartier-Harlin et al. 2004; Zarranz et al. 2004)
suggesting that alpha-synuclein is important in the regu-
lation of DA transmission. In a recent study, Senior et al.
(2008) found that mice lacking both alpha- and gamma-
synuclein proteins showed hyperactive behaviour in a
novel environment and a reduced alternate rate in the
T-maze spontaneous alternation task. These behaviours are
most likely associated with an increase in DA release. Both
the hyperactive behaviour and the deficit in working
memory show that this model has some face validity for
ADHD. The construct validity is given because of the
increase in DA release. However, hyperactive behaviour in
these mice is only present in a novel environment and the
activity in the home cage does not differ to the wild type. It
has been suggested that hyperactivity in a familiar envi-
ronment is a better indicator of ADHD-like hyperactivity
(Sagvolden et al. 2005). Furthermore, no data are available
with respect to attention deficits or impulsive behaviour.
The validity of this model of ADHD is so far only based on
hyperactive behaviour and alterations in the dopaminergic
system.
Pharmacological animal models of ADHD (Table 2)
Juvenile rodents with a neonatal 6-hydroxydopamine-
induced brain lesion
The experimental destruction of DA-containing neurons
with 6-hydroxydopamine (6-OHDA) in adult rats is an
established model of Parkinson’s disease. Lesions of the
dopaminergic system in neonatal rats lead to age-limited
spontaneous motor hyperactivity (Creese and Iversen 1973;
Heffner and Seiden 1982; Luthman et al. 1989, 1997;
Shaywitz et al. 1976a, b). Hyperactivity observed in this rat
is most prominent prior to puberty (Erinoff et al. 1979;
Shaywitz et al. 1976b; Zhang et al. 2002b) and can be
antagonized by stimulants (Davids et al. 2002; Heffner and
Seiden 1982; Luthman et al. 1989; Shaywitz et al. 1976a).
These deficits disappear in adult rats, probably due to
on-going developmental processes. Most behavioural def-
icits observed are based on acute adaptive alterations in the
dopaminergic system due to the 6-OHDA lesion. For
example, the remaining dopaminergic neurons release
more DA from their terminals (Carder et al. 1989;
Castaneda et al. 1990). Both presynaptic D2 autoreceptors
and DA transporters are reduced (Joyce et al. 1996;
Schwarting and Huston 1996). Further data suggest that
increased D4 receptor levels in the caudate-putamen cor-
relate with behavioural hyperactivity (Zhang et al. 2001).
Furthermore, the D4 receptor seems to be essential for
hyperactive behaviour (Avale et al. 2004a). Mice with
neonatal 6-OHDA lesions lacking the D4 receptor did not
show hyperactive behaviour compared to the wild type
(Avale et al. 2004a). This effect was not based on a dif-
ferent sensitivity to 6-OHDA since both genotypes showed
an equivalent degree of DA depletion. These findings are
important since a polymorphism of the D4 receptor has
been linked to ADHD (Faraone et al. 1999; Faraone and
Doyle 2001; Grady et al. 2003; LaHoste et al. 1996;
Swanson et al. 1998). This model appears therefore to be
useful in the investigation of the role of the D4 receptor in
ADHD.
The 6-OHDA lesion also affects other neurotransmitter
systems. For example, a serotonergic hyperinnervation of
the striatum was found (Descarries et al. 1992; Frohna
et al. 1997; Kostrzewa et al. 1998; Luthman et al. 1990;
Stachowiak et al. 1984; Towle et al. 1989; Zhang et al.
2002a). By contrast, no such changes were observed in the
noradrenergic system (Luthman et al. 1990; Ordway 1995).
A study by Avale et al. (2004b) suggests that the increase in
striatal serotonin is associated with hyperactive behaviour.
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Avale and colleagues treated mice with neonatal 6-OHDA
lesions with a tryptophan hydroxylase inhibitor in order to
normalize striatal serotonin without affecting DA levels.
These mice did not show hyperactive behaviour.
In summary, this model shows some predictive validity,
since treatment with psychostimulants reduces the hyper-
activity. Construct validity is given by the profound
changes in the catecholaminergic neurotransmitter system.
Finally, the hyperactivity of this model supports face
validity. In addition, this model enables the study of the
role of the D4 receptor and serotonin in ADHD. However,
data regarding impulsive behaviour or specific attentional
deficits are not available.
Neonatal hypoxia in rats
Hypoxia induced by nitrogen after birth has been shown to
induce ADHD-like behavioural deficits (Dell’Anna et al.
1993; Speiser et al. 1983, 1988) including age-limited
hyperactivity and deficits in learning and memory
(Gramatte and Schmidt 1986). The hyperactivity can be
counteracted with D-amphetamine (Speiser et al. 1983). As
shown following neonatal lesions, hypoxia induces several
adaptive monoaminergic alterations which change with age
(Dell’Anna et al. 1993). The acute effect is a decrease in
NA in the cortex and of DA in the striatum, while the
serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA)
is increased in both cortex and cerebellum (Dell’Anna et al.
1993). A week after hypoxia NA was increased in the
cerebellum, and serotonin and 5-HIAA were decreased in
both cerebellum and cortex. On postnatal day 21, NA in the
hippocampus and HVA in the striatum were increased. By
contrast, serotonin was decreased in the striatum with
increased levels of its metabolite 5-HIAA in striatum and
hippocampus. Finally, on postnatal day 60, DOPAC and
5-HIAA levels were increased in the striatum (Dell’Anna
et al. 1993).
The learning deficits reported might be related to mor-
phological changes in the hippocampus since neuronal
density was reduced in the CA1 region starting on postnatal
day 15, and indexes of neuronal repair could be observed
on postnatal day 7 (Dell’Anna et al. 1995).
It still remains to be established to what extent these
complex changes contribute to ADHD.
In summary, face validity of this model is based on
hyperactivity, while studies investigating attention deficits
or impulsivity are missing. The alterations in the cate-
cholaminergic system might have some construct validity.
However, it remains unclear whether these complex
changes reflect the symptoms of ADHD. Some predictive
validity is given by the effect of D-amphetamine on
hyperactivity.
Developmental cerebellar stunting in rats
A significantly reduced cerebellar volume in children with
ADHD has been reported (Castellanos et al. 1996b, 2001,
2002; Durston et al. 2004), suggesting a role of the cere-
bellum in ADHD. Animal models using lesions of the
cerebellum may therefore show some construct validity.
Various substances have been used for cerebellar lesions.
For example, the administration of metylazoxymethanol
(MAM) before postnatal day 4 resulted in hyperactivity
while treatment from postnatal day 4 onwards resulted in
Table 2 Pharmacological animal models of ADHD
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mild hyperactivity (Ferguson et al. 1996; Ferguson 1996,
2001). However, the treatment with amphetamine increased
the activity (Ferguson et al. 1996). The administration of
alpha-difluoromethylornithine (DFMO) on postnatal days
5–10 reduced cerebellar brain volume and affected cere-
bellar development but did not change open field behaviour
(Cada et al. 2000). The administration of dexamethason in
rats on postnatal day 7 has been shown to cause decreased
cerebellar volume and mild hyperactivity in an open field
(Ferguson and Holson 1999).
With regard to ADHD, lesions performed between
postnatal days 5 and 12 show some face validity because of
the hyperactivity observed. However, amphetamine treat-
ment increased the hyperactivity indicating that evidence
of predictive validity is missing. The criterion of construct
validity is difficult to judge since data on abnormal cate-
cholamine neurotransmitters are not available. Reductions
in cerebellar volume have been found in patients with
ADHD. However, it is not clear to what extent the cere-
bellum contributes to ADHD. Studies in primates have
shown a complex circuitry between cerebellum, basal
ganglia, PFC and pons (Middleton and Strick 1997a, b,
2001) Therefore, from an anatomical point of view, it
is possible that the cerebellum influences PFC activity.
In addition, Schmahmann and Sherman (1998) and
Schmahmann (2004) have postulated a cerebellar cognitive
affective syndrome, which has some behavioural similari-
ties with ADHD. In summary, this model may have
potential to study the role of the cerebellum in ADHD.
However, the data available at present are not sufficient to
describe cerebellar stunting as a valid model of ADHD.
Maternally stressed mice
A recent study by Son et al. (2007) has suggested the use of
maternally stressed adult mice as an animal model of
ADHD. It was found that the adult offspring of mice
treated with restraint stress during pregnancy were hyper-
active. These mice showed a reduced habituation to a novel
environment compared to control mice. Furthermore,
wheel-running activity was still increased in these mice
after three days of habituation. The use of a DA antagonist
reduced the wheel-running activity to the level of the
control mice, suggesting that the hyperactive behaviour is
associated with DA. The maternally stressed adult mice
also showed a reduced expression of the DAT and an
increased DA turnover in the striatum.
The maternally stressed adult mice have face validity
because of their hyperactive behaviour. Construct validity
is given because of the alteration in the dopaminergic
system. Furthermore, there are studies in humans sug-
gesting a correlation between stress during pregnancy and
the onset of ADHD (Laucht et al. 2000; McIntosh et al.
1995). However, further studies investigating attention,
impulsivity and cognitive deficits are necessary to validate
this model.
Discussion
Although ADHD is a common disorder among children
and adolescents, little is known about its neurobiological
basis. It has been suggested that disturbances within the
fronto-striatal system and altered levels of the neurotrans-
mitters DA and NA are involved in the pathophysiology of
ADHD. This is based on several indications. For example,
patients with prefrontal lesions show behavioural similar-
ities with ADHD patients (Benton 1991; Heilman et al.
1991; Levin 1938; Mattes 1980) and the right PFC volume
is reduced in children with ADHD (Castellanos et al.
1996b; Filipek et al. 1997; Hynd et al. 1990). Both basal
ganglia and frontal lobe volumes correlate with impaired
attention and inhibition (Casey et al. 1997; Semrud-
Clikeman et al. 2000). Finally, methylphenidate increases
the reduced blood flow in prefrontal regions of individuals
with ADHD (Langleben et al. 2002; Lou et al. 1984, 1989).
DA and NA are important neurotransmitters in these brain
regions, and a dysfunction of these neurotransmitters
appears to be likely. This is also underlined by the fact
that treatment with psychostimulants reduces ADHD
symptoms.
Different pathophysiological mechanisms have been
suggested on the basis of altered dopaminergic and nor-
adrenergic neurotransmission. For example, Arnsten et al.
(1996) have suggested a sole reduction in noradrenergic
function while Pliszka et al. (1996) postulated a combi-
nation of dopaminergic hypofunctioning and noradrenergic
dysfunctioning as the basis of the core symptoms of
ADHD. Studies investigating neurotransmitter levels in
patients revealed conflicting results. Some studies found
indications of an altered activity in catecholaminergic
metabolites (Oades et al. 1998; Shaywitz et al. 1977;
Shekim et al. 1977, 1979, 1983, 1987), while others found
no differences (Rapoport et al. 1978; Shetty and Chase
1976; Wender et al. 1971). However, it has to be consid-
ered that the patients investigated in these studies differed
with regard to comorbidity, medication and other relevant
factors. Catecholamine metabolites may not reflect the
neurochemical status of patients with ADHD since neither
plasma nor urinary levels of HVA and MHPG correlate
with hyperactivity or predict the response to stimulant
treatment (Castellanos et al. 1994, 1996a).
Given the high heritability of ADHD (Gilger et al. 1992;
Rhee et al. 1999), the investigation of genes involved in
catecholamine functioning is another research strategy.
Recent studies have suggested that both the DAT gene and
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the D4 receptor gene are associated with ADHD (Bobb
et al. 2005; DiMaio et al. 2003). However, several studies
were not able to establish any association (Bakker et al.
2005; Frank et al. 2004; Langley et al. 2004; Mill et al.
2004).
Although the available data clearly indicate that dopa-
minergic, noradrenergic and probably serotonergic activi-
ties within the fronto-striatal system play an important role
in ADHD, there is no prevailing concept of the neurobi-
ology of ADHD. This might reflect the heterogeneous
nature of ADHD, and it may not be reasonable to expect a
unique biological profile in ADHD.
Further knowledge about the neurobiology of ADHD
may be provided by animal models. However, these
models will provide reasonable conclusions only if certain
validation criteria are fulfilled.
Several animal models of ADHD have been proposed
(for review see also Kostrzewa et al. 2008; Russell et al.
2005; Sagvolden et al. 2005; van der Kooij and Glennon
2007), and most of these models were initially based on the
presence of hyperactivity. However, face validity of an
animal model of ADHD should also include impulsive
behaviour and attention deficits. In addition, deficits in
learning or executive functions might also be indicators of
face validity. Investigations concerning impulsivity and
attention deficits are still missing for some of the ADHD
models including the acallosal mouse, the neonatal
6-OHDA lesion model, the neonatal hypoxia model, the
NHE rat, the DAT-KO mouse and the developmental
cerebellar stunting model. Further research is therefore
needed in order to validate these models regarding face
validity. Most of these models have predictive validity
since treatment with psychostimulants reduces hyperac-
tivity. It has sometimes been argued that good predictive
validity is given only if both amphetamine and methyl-
phenidate are effective in these models. However, the fact
that there are responders and non-responders to methyl-
phenidate among patients with ADHD suggests different
types of pathophysiology in ADHD. Differential response
to amphetamine and methylphenidate in animal models
might therefore reflect different pathophysiological mech-
anisms. Data concerning predictive validity are not avail-
able for the acallosal mouse and the NHE rat, while the
treatment of the developmental cerebellar stunting rat with
amphetamine leads to an increase in hyperactivity.
With regard to construct validity, alterations in dopa-
minergic or noradrenergic activities have been reported for
all models except the acallosal mouse and developmental
cerebellar stunting. The validity of these two models of
ADHD is therefore limited. However, the developmental
cerebellar stunting rat might have some potential as an
animal model, since human studies have suggested a role
of the cerebellum in ADHD. Not all models fulfil therefore
the criteria necessary. The SHR is the best studied animal
model with regard to validity. However, the hypertension
in this rat and the use of the WKY rat as control in most
studies put in question the use of SHRs as an animal model
of ADHD.
Even if all criteria are fulfilled, the models show differ-
ences. For example, the SHR shows an impaired DA
release, and both neonatal 6-OHDA-lesion rat and colo-
boma mouse have a decreased DA transmission while the
DAT-KO mouse shows an increased DA transmission.
Nevertheless, all these animals present with symptoms of
ADHD, namely hyperactivity. Both increased and
decreased dopaminergic activity can therefore lead to
ADHD-like symptoms. This suggests that a dysbalance
between presynaptic and postsynaptic activities might be
important. There is a similar problem with noradrenergic
activity in these models. Pliszka et al. (1996) and Arnsten
et al. (1996) have postulated a decreased noradrenergic
function in ADHD. Depletion of NA in neonatal rats by
administering 6-OHDA in combination with a selective
DAT-inhibitor (Teicher et al. 1986) has been shown to
induce motor hyperactivity (Raskin et al. 1983), learning
deficits (Roberts et al. 1976) and attention deficits (Carli
et al. 1983). The main source of central NA is the LC, which
innervates the entire cerebral cortex, various subcortical
areas, cerebellum and spinal cord. The LC has been found to
play an important role in attention, arousal, orientation and
vigilance (Solanto 1998) since its neurons selectively
respond to target stimuli. Tonic LC activity corresponds
with the arousal state, and both very low and very high LC
activities are associated with impaired vigilance (Arnsten
1997; Aston-Jones et al. 1994). However, the above-men-
tioned animal models show either unaltered noradrenergic
functioning or an increase in NA functions, while none of
the models show a decrease in noradrenergic activity.
Based on the SHR model, one might conclude that
increased noradrenergic activity and decreased dopami-
nergic activity represent the characteristic dysbalance of
catecholamines in ADHD. However, there are indications
that the opposite might also be true, i.e. both increased and
decreased dopaminergic activity can lead to ADHD-like
symptoms. The same appears to hold true for noradrenergic
activity. Furthermore, the increase in noradrenergic activity
in the SHR is closely connected to hypertension, which is
one of the most confounding factors in this animal model.
The question therefore arises, which model best repre-
sents the nature of ADHD. So far, studies with patients
have only shown that the structural alterations in the
fronto-striatal-cerebellar system, functional alterations in
catecholaminergic systems and genes coding for the DAT
and the D4-receptor are associated with ADHD. In regard
to construct validity in ADHD animal models, this means
that every animal with alterations in these systems has
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some construct validity for ADHD. Therefore, it is the
combination of face, predictive and construct validity that
makes an animal model more or less valid. This illustrates
the basic problem in validating animal models: the more is
known about the biology of a disease the more conclusive
is the comparison between animal model and modelled
disease. However, it is the lack of information that makes it
necessary to develop a model in order to learn more about
the biology of the modelled disease.
Conclusion
There are several animal models of ADHD and some of
them fulfil all criteria necessary for a valid model. The
currently proposed models are heterogeneous with regard
to their pathophysiological alterations and their ability to
mimic behavioural symptoms and to predict response to
medication. This might reflect the heterogeneous nature of
ADHD. Since our knowledge about the neurobiology of
ADHD from human studies is limited, one cannot at
present decide, which model best represents ADHD or
certain ADHD subtypes. Animal models with good face
and predictive validity may be useful for investigations of
the underlying biological substrates of ADHD. At present,
the models in use should be described as animal models of
ADHD-like symptoms rather than models of ADHD.
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